Probiotec Limited
PBP.AX
Australian Securities Exchange2.98
AUD
-0.01
- -
ISIN
AU000000PBP7
CUSIP
Q7746U109
Return %
Stock
S&P500
1Y
11.19
26.84
3Y
43.96
77.03
5Y
77.38
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Wesley Stringer CPA, LLB
- Full Time Employees
- 111
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 83 Cherry Lane Laverton North VIC Australia 3026
- IPO Date
- Nov 13, 2006
- Website
- probiotec.com.au
- Similar Companies
- Business
- Probiotec Limited engages in the contract development, manufacture, packaging, distribution and sale of prescription and over-the-counter pharmaceuticals, complementary medicines, consumer health products, nutraceuticals, fast-moving consumer goods and animal health products primarily in Australia. The company offers contract manufacturing services for solid dose tablets, capsules and caplets; tablet coatings; liquids, creams, gels, lotions, ointments and suspensions; powders and powder blends including pharmaceutical, nutraceutical and functional ingredients; sprays; and blister packs, bottles, sachets, tubs and tubes; alongside analytical and stability testing, new product formulation, production trials, ongoing research and development, and secondary co-packing for food and beverage, personal care, household, animal nutrition and fast-moving consumer goods through subsidiaries and divisions including Probiotec Pharma, Probiotec Multipack, LJM, ABS and South Pack Laboratories. Probiotec Limited operates six advanced facilities across New South Wales and Victoria, with its headquarters in Laverton North, Victoria; it was founded in 1997 and maintains Therapeutic Goods Administration, HACCP, APVMA and cGMP certifications. In June 2024, PYFA Australia Pty Ltd, a subsidiary of Indonesia-listed PT Pyridam Farma Tbk, completed the acquisition of the remaining 89.67% stake in Probiotec Limited for approximately AUD 240 million, delisting the company from the ASX; new directors Jared Stringer and Andrew Phillips were appointed, and in September 2024, the company aligned its financial year-end with its parent's calendar year pursuant to ASIC relief. Probiotec Limited supports global market leaders with high-quality, innovative production and invests heavily in research, development and advanced technologies to meet stringent Australian manufacturing standards.